Gen inCode develops patented DNA risk assessment products that combine AI, bioinformatics and a clinical evidence base to deliver predictive analysis of patient health risk. Its proprietary algorithms predict the probability of adverse events to produce comprehensive, clinically actionable risk evaluations. The company’s advanced diagnostic tests cover major disease areas including cardiovascular disease, cancer and diabetes and aim to help clinicians identify high-risk patients and target prevention and treatment plans. Gen inCode was founded in 2018 after acquiring the assets of Ferrer inCode and Gendiag.exe and has built a strong IP portfolio. The business says the recent institutional funding will enable overseas expansion, with particular focus on the US, and support its regulatory and clinical pathway into that market. Management highlights the opportunity to capitalise on growth in the emerging precision medicine market.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2020